相关实验视频

Updated: Jan 14, 2026

Basophil Activation Test for Allergy Diagnosis

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

血管控制试验与遗传性血管发作的发作频率之间的关联

Aaron Yarlas¹, Alexandra J Feld², Jakob B Bjorner²

¹Ionis Pharmaceuticals Inc., Carlsbad, California, USA.

Clinical and translational allergy

|January 12, 2026

概括

血管控制试验 (AECT) 准确地反映了遗传性血管 (HAE) 疾病控制. AECT得分与HAE攻击率相关,验证了其在临床实践中的使用.

科学领域:

免疫学免疫学免疫学
遗传学是一个遗传学.
临床试验临床试验

背景情况:

遗传性血管 (HAE) 导致不可预测的胀发作,影响生活质量.
在日常护理中,评估HAE疾病活性和治疗反应是具有挑战性的.
血管控制试验 (AECT) 是患者报告的HAE疾病控制措施.

研究的目的:

为了评估AECT的标准有效性.
评估AECT得分与HAE疾病控制的客观指标之间的相关性,特别是HAE攻击率.

主要方法:

对第3期OASIS-HAE研究 (NCT05139810) 的后期分析.
患有HAE的患者在24周内接受了donidalorsen或安慰剂.
研究人员在基线,第12周和第24周检查了AECT得分与研究者确认的HAE攻击率之间的相关性.

主要成果:

AECT得分与HAE发作率 (ρ = -0.40至 -0.85) 有中度至强度的相关性.
在控制不良 (AECT < 10) 和控制良好 (AECT ≥ 10) HAE的患者之间观察到平均发作率的显著差异.
实现完全疾病控制的患者 (AECT=16) 在第24周的发作率为0或1次.

结论:

这项研究支持AECT在HAE患者的标准有效性.
AECT得分与HAE疾病控制的客观措施密切相关.
在临床实践中,AECT是监测HAE疾病控制的宝贵工具.

关键词:

这就是AECT AECT.在HAEAE中.疾病控制疾病控制患者报告的结果.的有效性有效性.

更多相关视频

Measuring Local Anaphylaxis in Mice

Measuring Local Anaphylaxis in Mice

Published on: October 14, 2014

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

相关概念视频

Allergic Reactions

Allergic Reactions

Angina III: Clinical Manifestations and Assessment

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...